Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label safety and tolerability study of SB206 in Japanese subjects with molluscum contagiosum
jRCT2031230123Completed
- Sponsor
- Sato Pharmaceutical
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of berdazimer in molluscum contagiosum (MC), sponsored by Sato Pharmaceutical. Primary endpoint: Safety and tolerability of SB206. Started Jun 2023; status: completed.
02
Drugs
berdazimer
03
Conditions
molluscum contagiosum (MC)
Beyond the preview
Go deeper on jRCT2031230123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230123.